Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab + Cisplatin + Capecitabine in First-Line Metastatic Gastric Cancer
NCT02314117Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2015
- Primary completion
- Jan 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Ramucirumab Arm with Placebo Arm (2 arms). Primary endpoint: Progression-free Survival up to 26 Months. Started Jan 2015; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02314117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02314117.